A glycosylated conserved portion of the variable region 3, termed “glycan V3” on HIV-1 gp120, is another vaccine target of importance (reviewed in [24]) (Fig. 4a); notably, the glycan V3 supersite is recognized by the most common broadly neutralizing antibodies elicited during the first two to three years of infection. The gene discussed is ITIH4; the disease is infection.